The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778
2023
Details
- Autor(en) / Beteiligte
- Titel
- Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
- Ist Teil von
- The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In patients with advanced renal-cell carcinoma, treatment with cabozantinib plus nivolumab and ipilimumab resulted in longer progression-free survival than treatment with nivolumab and ipilimumab alone.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2212851Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10257898
- Format
- –
- Schlagworte
- Adverse events, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Body weight, Cancer, Carcinoma, Renal Cell - drug therapy, Carcinoma, Renal Cell - mortality, Carcinoma, Renal Cell - pathology, Confidence intervals, Double-Blind Method, Genitourinary Cancer, Hematology, Humans, Immunology, Immunotherapy, Inhibitor drugs, Ipilimumab - administration & dosage, Ipilimumab - adverse effects, Ipilimumab - therapeutic use, Kidney cancer, Kidney Neoplasms - drug therapy, Kidney Neoplasms - mortality, Kidney Neoplasms - pathology, Metastases, Metastasis, Monoclonal antibodies, Nephrology, Nephrology General, Nivolumab - administration & dosage, Nivolumab - adverse effects, Nivolumab - therapeutic use, Oncology, Prognosis, Renal cell carcinoma, Solid tumors, Survival Analysis, Targeted cancer therapy, Treatments in Oncology